APOC3_RAT
ID APOC3_RAT Reviewed; 101 AA.
AC P06759;
DT 01-JAN-1988, integrated into UniProtKB/Swiss-Prot.
DT 30-MAY-2000, sequence version 2.
DT 03-AUG-2022, entry version 124.
DE RecName: Full=Apolipoprotein C-III;
DE Short=Apo-CIII;
DE Short=ApoC-III;
DE AltName: Full=Apolipoprotein C3;
DE Flags: Precursor;
GN Name=Apoc3;
OS Rattus norvegicus (Rat).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC Eutheria; Euarchontoglires; Glires; Rodentia; Myomorpha; Muroidea; Muridae;
OC Murinae; Rattus.
OX NCBI_TaxID=10116;
RN [1]
RP NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND TISSUE SPECIFICITY.
RX PubMed=3020028; DOI=10.1016/s0021-9258(18)69300-7;
RA Haddad I.A., Ordovas J.M., Fitzpatrick T., Karathanasis S.K.;
RT "Linkage, evolution, and expression of the rat apolipoprotein A-I, C-III,
RT and A-IV genes.";
RL J. Biol. Chem. 261:13268-13277(1986).
RN [2]
RP SEQUENCE REVISION TO 60.
RA Haddad I.A., Ordovas J.M., Fitzpatrick T., Karathanasis S.K.;
RL Submitted (DEC-1998) to the EMBL/GenBank/DDBJ databases.
CC -!- FUNCTION: Component of triglyceride-rich very low density lipoproteins
CC (VLDL) and high density lipoproteins (HDL) in plasma. Plays a
CC multifaceted role in triglyceride homeostasis. Intracellularly,
CC promotes hepatic very low density lipoprotein 1 (VLDL1) assembly and
CC secretion; extracellularly, attenuates hydrolysis and clearance of
CC triglyceride-rich lipoproteins (TRLs). Impairs the lipolysis of TRLs by
CC inhibiting lipoprotein lipase and the hepatic uptake of TRLs by remnant
CC receptors. Formed of several curved helices connected via semiflexible
CC hinges, so that it can wrap tightly around the curved micelle surface
CC and easily adapt to the different diameters of its natural binding
CC partners. {ECO:0000250|UniProtKB:P02656}.
CC -!- SUBCELLULAR LOCATION: Secreted {ECO:0000250|UniProtKB:P02656}.
CC -!- TISSUE SPECIFICITY: Synthesized predominantly in liver and to a lesser
CC degree in intestine. {ECO:0000269|PubMed:3020028}.
CC -!- PTM: The most abundant glycoforms are characterized by an O-linked
CC disaccharide galactose linked to N-acetylgalactosamine (Gal-GalNAc),
CC further modified with up to 3 sialic acid residues. Less abundant
CC glycoforms are characterized by more complex and fucosylated glycan
CC moieties. O-glycosylated on Thr-96 with a core 1 or possibly core 8
CC glycan. {ECO:0000250|UniProtKB:P02656}.
CC -!- SIMILARITY: Belongs to the apolipoprotein C3 family. {ECO:0000305}.
CC ---------------------------------------------------------------------------
CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC ---------------------------------------------------------------------------
DR EMBL; J02596; AAA40746.1; -; Genomic_DNA.
DR PIR; B24700; B24700.
DR AlphaFoldDB; P06759; -.
DR SMR; P06759; -.
DR STRING; 10116.ENSRNOP00000067045; -.
DR GlyGen; P06759; 1 site.
DR iPTMnet; P06759; -.
DR PhosphoSitePlus; P06759; -.
DR PaxDb; P06759; -.
DR PRIDE; P06759; -.
DR RGD; 2136; Apoc3.
DR eggNOG; ENOG502SZ00; Eukaryota.
DR HOGENOM; CLU_154694_0_0_1; -.
DR InParanoid; P06759; -.
DR PhylomeDB; P06759; -.
DR Reactome; R-RNO-8963888; Chylomicron assembly.
DR Reactome; R-RNO-8963901; Chylomicron remodeling.
DR Reactome; R-RNO-8964058; HDL remodeling.
DR Reactome; R-RNO-975634; Retinoid metabolism and transport.
DR PRO; PR:P06759; -.
DR Proteomes; UP000002494; Unplaced.
DR Genevisible; P06759; RN.
DR GO; GO:0042627; C:chylomicron; ISO:RGD.
DR GO; GO:0005615; C:extracellular space; IDA:RGD.
DR GO; GO:0034363; C:intermediate-density lipoprotein particle; ISO:RGD.
DR GO; GO:0034366; C:spherical high-density lipoprotein particle; ISO:RGD.
DR GO; GO:0034361; C:very-low-density lipoprotein particle; ISO:RGD.
DR GO; GO:0030234; F:enzyme regulator activity; ISO:RGD.
DR GO; GO:0070653; F:high-density lipoprotein particle receptor binding; ISO:RGD.
DR GO; GO:0055102; F:lipase inhibitor activity; ISO:RGD.
DR GO; GO:0005319; F:lipid transporter activity; TAS:RGD.
DR GO; GO:0005543; F:phospholipid binding; ISO:RGD.
DR GO; GO:0071333; P:cellular response to glucose stimulus; IDA:RGD.
DR GO; GO:0033344; P:cholesterol efflux; ISO:RGD.
DR GO; GO:0042632; P:cholesterol homeostasis; ISO:RGD.
DR GO; GO:0008203; P:cholesterol metabolic process; ISO:RGD.
DR GO; GO:0034382; P:chylomicron remnant clearance; ISO:RGD.
DR GO; GO:0007186; P:G protein-coupled receptor signaling pathway; ISO:RGD.
DR GO; GO:0034375; P:high-density lipoprotein particle remodeling; ISO:RGD.
DR GO; GO:0006954; P:inflammatory response; IEP:RGD.
DR GO; GO:0006869; P:lipid transport; TAS:RGD.
DR GO; GO:0042157; P:lipoprotein metabolic process; IEA:InterPro.
DR GO; GO:0042953; P:lipoprotein transport; IDA:RGD.
DR GO; GO:0060621; P:negative regulation of cholesterol import; ISO:RGD.
DR GO; GO:0045717; P:negative regulation of fatty acid biosynthetic process; ISO:RGD.
DR GO; GO:0010987; P:negative regulation of high-density lipoprotein particle clearance; ISO:RGD.
DR GO; GO:0050995; P:negative regulation of lipid catabolic process; ISO:RGD.
DR GO; GO:0045833; P:negative regulation of lipid metabolic process; ISO:RGD.
DR GO; GO:0051005; P:negative regulation of lipoprotein lipase activity; ISO:RGD.
DR GO; GO:0010989; P:negative regulation of low-density lipoprotein particle clearance; ISO:RGD.
DR GO; GO:0090324; P:negative regulation of oxidative phosphorylation; IDA:RGD.
DR GO; GO:0048261; P:negative regulation of receptor-mediated endocytosis; ISO:RGD.
DR GO; GO:0010897; P:negative regulation of triglyceride catabolic process; ISO:RGD.
DR GO; GO:0010916; P:negative regulation of very-low-density lipoprotein particle clearance; ISO:RGD.
DR GO; GO:0010903; P:negative regulation of very-low-density lipoprotein particle remodeling; ISO:RGD.
DR GO; GO:0033700; P:phospholipid efflux; ISO:RGD.
DR GO; GO:0010867; P:positive regulation of triglyceride biosynthetic process; IMP:RGD.
DR GO; GO:0032489; P:regulation of Cdc42 protein signal transduction; ISO:RGD.
DR GO; GO:0070542; P:response to fatty acid; IEP:RGD.
DR GO; GO:0007584; P:response to nutrient; IEP:RGD.
DR GO; GO:0043434; P:response to peptide hormone; IDA:RGD.
DR GO; GO:0034014; P:response to triglyceride; IEP:RGD.
DR GO; GO:0033189; P:response to vitamin A; IEP:RGD.
DR GO; GO:0009410; P:response to xenobiotic stimulus; IEP:RGD.
DR GO; GO:0019433; P:triglyceride catabolic process; ISO:RGD.
DR GO; GO:0070328; P:triglyceride homeostasis; ISO:RGD.
DR GO; GO:0006641; P:triglyceride metabolic process; ISO:RGD.
DR GO; GO:0006642; P:triglyceride mobilization; ISO:RGD.
DR Gene3D; 6.10.90.10; -; 1.
DR InterPro; IPR008403; Apo-CIII.
DR InterPro; IPR038195; Apo_CIII_sf.
DR PANTHER; PTHR14225; PTHR14225; 1.
DR Pfam; PF05778; Apo-CIII; 1.
PE 2: Evidence at transcript level;
KW Chylomicron; Glycoprotein; Lipid degradation; Lipid metabolism;
KW Lipid transport; Oxidation; Reference proteome; Secreted; Sialic acid;
KW Signal; Transport; VLDL.
FT SIGNAL 1..20
FT /evidence="ECO:0000255"
FT CHAIN 21..101
FT /note="Apolipoprotein C-III"
FT /id="PRO_0000002035"
FT REGION 69..101
FT /note="Lipid-binding"
FT /evidence="ECO:0000250"
FT SITE 41
FT /note="May interact with the LDL receptor"
FT /evidence="ECO:0000250|UniProtKB:P02656"
FT MOD_RES 64
FT /note="Methionine sulfoxide"
FT /evidence="ECO:0000250|UniProtKB:P33622"
FT CARBOHYD 96
FT /note="O-linked (GalNAc...) threonine"
FT /evidence="ECO:0000250|UniProtKB:P02656"
SQ SEQUENCE 101 AA; 11117 MW; 1A7260DB909692D2 CRC64;
MQPRMLLIVA LVALLASARA DEGEGSLLLG SMQGYMEQAS KTVQDALSSM QESDIAVVAS
RGWMDNRFKS LKGYWSKFTD KFTGLWESGP EDQLTTPTLE P
